When procurement agencies, hospital networks, and international distributors choose a manufacturing partner, they are making a decision that will affect supply chains for years. This page explains why Laborate is that decision for more than 35 markets worldwide.
What partners consistently tell us they were looking for was not the lowest price. It was a manufacturer they could not outgrow — one that could respond to volume changes without compromising quality, navigate regulatory submissions without adding delay, and maintain consistent standards across every production run, every year.
Laborate is not the largest pharmaceutical manufacturer in India. It is, however, one of the most consistently reliable. That distinction has been built over four decades — not through marketing campaigns, but through the compounding effect of keeping commitments, passing audits, and delivering product that meets specification, every time.
The case for Laborate is not made by Laborate. It is made by the WHO audit records, the USFDA site clearances, the Pharmexcil Gold Awards, and the procurement offices across 35 countries that continue to renew supply agreements year after year.
Every pharmaceutical company claims quality. These are the specific, auditable, operational facts that distinguish Laborate from the broader market — the eight reasons that procurement decisions hold year after year.
Five WHO-GMP certified manufacturing plants with a combined capacity exceeding 1.5 million dosage units per day. Multiple sites mean redundancy — a supply disruption at one facility does not become a supply disruption for the customer.
Over 1,500 formulations across 15 therapeutic categories — tablets, capsules, injectables, syrups, ointments, and ophthalmic preparations. A partner can consolidate procurement from one qualified source rather than managing five separate suppliers.
Quality management is not a department at Laborate — it is the operating system. ISO 9001, ISO 14001, and ISO 45001 are active across all plants. In-house analytical labs validate every batch, and every deviation is formally investigated.
WHO Prequalification, EU GMP certification, USFDA voluntary site inspection clearance, PIC/S compliance, and Schedule M alignment — across all five facilities. Regulatory readiness is embedded in the manufacturing process, not retrofitted before an audit.
No critical API sourced from a single supplier. Strategic inventory buffers for 14 high-demand active ingredients. Logistics partnerships with bonded freight forwarders in 8 ports. The chain is designed to absorb disruption, not propagate it.
Active export presence in 35+ regulated markets with established documentation processes for each regulatory jurisdiction — certificate of analysis, country-specific dossier formats, and in-country registration support for over 20 territories.
Every export account is assigned a relationship manager with pharmaceutical regulatory training. Technical queries receive documented responses within 48 hours. Regulatory dossier preparation, batch certificate management, and shipment tracking are handled without the customer needing to chase.
Continuous formulation development for new therapeutic categories and generic opportunities. Partners gain early access to pipeline molecules for market registration. R&D is structured for both innovation and volume — new formulations are designed for manufacturing scalability from the first prototype.
From the first enquiry to a long-term supply relationship — a Laborate partnership is structured, responsive, and transparent at every stage. This is the complete journey, and what you can expect from us at each step.
Initial enquiry assessed within 48 hours. Regulatory eligibility confirmed. Relationship manager assigned.
Product specifications reviewed. Packaging requirements confirmed. Stability and shelf-life parameters shared.
Dossier preparation and submission support. Country-specific documentation. Registration tracking provided.
WHO-GMP controlled production. Batch records maintained. Production schedule communicated in advance.
Full analytical testing. Certificate of analysis issued. Pre-shipment samples available on request.
Cold-chain or ambient dispatch. GDP-compliant handling. Real-time shipment tracking shared with partner.
Post-delivery support. Complaint resolution within defined SLAs. Annual business review with your relationship manager.
Formulations in active production
Across 15 therapeutic categories
WHO-GMP certified manufacturing plants
All five independently audited
Years of uninterrupted operations
Founded Panipat, 1985
Export markets worldwide
Regulated and emerging
SKUs across divisions
Tablets, injectables, liquids, topicals
Each of Laborate's five manufacturing facilities is independently WHO-GMP certified. They are not equivalent — they are purpose-built for specific dosage forms: solid orals, sterile injectables, liquids, topicals, and ophthalmic preparations. Specialisation at the facility level means each plant operates at the highest standard for its category.
“Every business decision at Laborate is filtered through a single test: does this protect, or compromise, the quality of the medicine that will reach the patient?”
Raw material suppliers are qualified through a formal vendor assessment process. No API or excipient enters a Laborate facility without documented supplier qualification and incoming material testing. A cheaper source that has not passed qualification does not enter the supply chain, regardless of the price difference.
Capacity expansion decisions at Laborate require QA sign-off alongside commercial approval. A plant cannot be pushed beyond its validated capacity without a formal change control. Volume growth is never permitted to compromise product quality — the system is designed to resist that pressure.
Laborate does not self-certify its quality. It invites audit. WHO inspectors, regulatory authority auditors, and third-party pharmacopoeial bodies have each independently confirmed compliance. The Quality page documents the full regulatory record. This page makes the business implication clear: our quality is not a claim.
Laborate's customer base spans the full healthcare supply chain — from government tenders to private label manufacturing. Breadth without fragmentation: each segment is served by a dedicated team within Laborate's divisional structure.
National health programmes, tender supply, essential medicine list formulations
Inpatient formularies, hospital networks, specialist care facilities
Consumer-facing formulations, OTC products, retail chains and independents
Regulated-market distributors, WHO PQ channels, PAHO and UNICEF supply routes
Global health programmes, humanitarian procurement, donor-funded supply chains
Own-brand formulation manufacturing, custom packaging, third-party manufacturing agreements
Contract development, scale-up, validation, and commercial manufacturing for partner molecules
Laborate's oldest supply relationships span more than 20 years. These are not retained through competitive pricing alone — they are retained through consistent quality, responsive communication, and regulatory dependability that makes switching away carry more risk than it is worth.
Dr. Meena Krishnamurthy Director, Procurement Services — State Health Authority“In 14 years of supply, I cannot recall a single batch rejection. That is not something you take for granted in pharmaceutical procurement. When we extend our supply agreement with Laborate, it is not a commercial decision — it is a quality risk management decision.”
Mr. James Ogola Procurement Manager — East Africa Health Programme“Regulatory dossier preparation is where many manufacturers create friction. Laborate prepares country-specific documentation proactively. That single capability has allowed us to register products in three new markets in the same cycle.”
Ms. Priya Nair Managing Director — Pan-Asian Pharma Distribution“We distribute to 12 countries, each with different regulatory requirements. Most manufacturers cannot manage that complexity. Laborate handles the documentation, the labelling variants, and the certificates without requiring us to manage the process ourselves.”
Our promise to every partner is the same as our promise to every patient: never compromise on quality, never compromise on reliability. That promise is not written in marketing copy. It is written in audit records, batch certificates, and supply agreements that have been renewed — year after year — by people who had the option not to.
Laborate Pharmaceuticals India Ltd. — Est. 1985, PanipatWhether you are looking for a reliable supply partner for regulated markets, a CDMO for your pipeline molecule, or a private label manufacturer for a new brand — our business development team is ready for the conversation.
